TFFP Key Statistics, Chart & Performance
The current stock price of TFFP is 0.065 USD. In the past month the price decreased by -96.13%. In the past year, price decreased by -99.17%.
TFFP Technical Analysis
TFFP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TFFP. TFFP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TFFP Financial Highlights
Over the last trailing twelve months TFFP reported a non-GAAP Earnings per Share(EPS) of -6.44. The EPS increased by 50.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -261.68% | ||
| ROE | -590.38% | ||
| Debt/Equity | 0 |
TFFP Forecast & Estimates
7 analysts have analysed TFFP and the average price target is 30.6 USD. This implies a price increase of 46976.92% is expected in the next year compared to the current price of 0.065.
For the next year, analysts expect an EPS growth of 65.1% and a revenue growth 60.13% for TFFP
TFFP Ownership
About TFFP
Company Profile
TFF Pharmaceuticals, Inc. engages in the development and commercialization of drug products based on its patented Thin Film Freezing technology platform. The company is headquartered in Austin, Texas and currently employs 19 full-time employees. The company went IPO on 2019-10-25. The company is focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform. Its TFF technology platform has an applicability to convert any drug, including vaccines, small and large molecules, and biologics, into a dry powder for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF TAC (Tacrolimus Inhalation Powder) and TFF VORI (Voriconazole Inhalation Powder). TFF TAC is an inhaled dry powder formulation of tacrolimus, for the prophylaxis of organ rejection in patients receiving lung transplants, in combination with other immunosuppressants. TFF VORI is an inhaled dry powder formulation of voriconazole, for the treatment and prophylaxis of invasive pulmonary aspergillosis.
Company Info
TFF Pharmaceuticals Inc
2600 Via Fortuna Ste 360
Austin TEXAS 78746 US
CEO: Glenn Mattes
Employees: 19
Phone: 17378021973
TFF Pharmaceuticals Inc / TFFP FAQ
What does TFFP do?
TFF Pharmaceuticals, Inc. engages in the development and commercialization of drug products based on its patented Thin Film Freezing technology platform. The company is headquartered in Austin, Texas and currently employs 19 full-time employees. The company went IPO on 2019-10-25. The company is focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform. Its TFF technology platform has an applicability to convert any drug, including vaccines, small and large molecules, and biologics, into a dry powder for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF TAC (Tacrolimus Inhalation Powder) and TFF VORI (Voriconazole Inhalation Powder). TFF TAC is an inhaled dry powder formulation of tacrolimus, for the prophylaxis of organ rejection in patients receiving lung transplants, in combination with other immunosuppressants. TFF VORI is an inhaled dry powder formulation of voriconazole, for the treatment and prophylaxis of invasive pulmonary aspergillosis.
What is the current price of TFFP stock?
The current stock price of TFFP is 0.065 USD. The price decreased by -60.05% in the last trading session.
Does TFFP stock pay dividends?
TFFP does not pay a dividend.
What is the ChartMill rating of TFF Pharmaceuticals Inc stock?
TFFP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the expected growth for TFFP stock?
The Revenue of TFF Pharmaceuticals Inc (TFFP) is expected to grow by 60.13% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for TFF Pharmaceuticals Inc?
TFF Pharmaceuticals Inc (TFFP) currently has 19 employees.
What is TFF Pharmaceuticals Inc worth?
TFF Pharmaceuticals Inc (TFFP) has a market capitalization of 288.60K USD. This makes TFFP a Nano Cap stock.